ABOUT US
CONTACT US
FAQ
PRIVACY POLICY
REFUND AND CANCELLATION
BLOGS
COMPANIES
REPORTS
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Omalizumab Biosimilars Market Research Report 2025
Published Date: February 2025
|
Report Code: QYRE-Auto-26N9928
Home | Market Reports | Business & Industrial| Pharmaceuticals & Biotech
Global Omalizumab Biosimilars Market Research Report 2022
BUY CHAPTERS

Global Omalizumab Biosimilars Market Research Report 2025

Code: QYRE-Auto-26N9928
Report
February 2025
Pages:90
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES
FEATURED COMPANIES
Roche
Novartis
Glenmark Pharmaceuticals
Selexis
Generium
Celltrion Healthcare
Alvotech
CSPC Pharmaceutical Group
CuraTeQ
BiosanaPharma
Mabpharm
Biomabs
HisunPharm

Omalizumab Biosimilars Market Size

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years.

Omalizumab Biosimilars Market

Omalizumab Biosimilars Market

The global market for Omalizumab Biosimilars was valued at US$ million in the year 2024 and is projected to reach a revised size of US$ million by 2031, growing at a CAGR of %during the forecast period.
Omalizumab is a medication used to treat asthma, nasal polyps, and urticaria. Omalizumab is a recombinant DNA-derived humanized IgG1k monoclonal antibody that specifically binds to free human immunoglobulin E (IgE) in the blood and interstitial fluid and to membrane-bound form of IgE (mIgE) on the surface of mIgE-expressing B lymphocytes. Unlike an ordinary anti-IgE antibody, it does not bind to IgE that is already bound by the high affinity IgE receptor (FcεRI) on the surface of mast cells, basophils, and antigen-presenting dendritic cells.
The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Omalizumab Biosimilars, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Omalizumab Biosimilars.
The Omalizumab Biosimilars market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Omalizumab Biosimilars market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Omalizumab Biosimilars manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Scope of Omalizumab Biosimilars Market Report

Report Metric Details
Report Name Omalizumab Biosimilars Market
CAGR 5%
Segment by Type
  • 150 mg/mL
  • 75 mg/0.5 mL
Segment by Application
Consumption by Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia)
  • Asia-Pacific (China, Japan, South Korea, Taiwan)
  • Southeast Asia (India)
  • Latin America (Mexico, Brazil)
By Company Roche, Novartis, Glenmark Pharmaceuticals, Selexis, Generium, CuraTeQ, Celltrion Healthcare, Alvotech, BiosanaPharma, Mabpharm, CSPC Pharmaceutical Group, Biomabs, HisunPharm
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Core Chapters

  • Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
  • Chapter 2: Detailed analysis of Omalizumab Biosimilars manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
  • Chapter 3: Sales, revenue of Omalizumab Biosimilars in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
  • Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
  • Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
  • Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
  • Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
  • Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
  • Chapter 9: The main points and conclusions of the report. 

FAQ for this report

Who are the main players in the Omalizumab Biosimilars Market report?

Ans: The main players in the Omalizumab Biosimilars Market are Roche, Novartis, Glenmark Pharmaceuticals, Selexis, Generium, CuraTeQ, Celltrion Healthcare, Alvotech, BiosanaPharma, Mabpharm, CSPC Pharmaceutical Group, Biomabs, HisunPharm

What are the Application segmentation covered in the Omalizumab Biosimilars Market report?

Ans: The Applications covered in the Omalizumab Biosimilars Market report are Persistent Asthma, Nasal Polyps, Chronic Idiopathic Urticaria

What are the Type segmentation covered in the Omalizumab Biosimilars Market report?

Ans: The Types covered in the Omalizumab Biosimilars Market report are 150 mg/mL, 75 mg/0.5 mL

Recommended Reports

Allergy & Asthma

Biosimilars & Biologics

Immunology & Antibodies

1 Omalizumab Biosimilars Market Overview
1.1 Product Definition
1.2 Omalizumab Biosimilars by Type
1.2.1 Global Omalizumab Biosimilars Market Value Comparison by Type (2024 VS 2031)
1.2.2 150 mg/mL
1.2.3 75 mg/0.5 mL
1.3 Omalizumab Biosimilars by Application
1.3.1 Global Omalizumab Biosimilars Market Value by Application (2024 VS 2031)
1.3.2 Persistent Asthma
1.3.3 Nasal Polyps
1.3.4 Chronic Idiopathic Urticaria
1.4 Global Omalizumab Biosimilars Market Size Estimates and Forecasts
1.4.1 Global Omalizumab Biosimilars Revenue 2020-2031
1.4.2 Global Omalizumab Biosimilars Sales 2020-2031
1.4.3 Global Omalizumab Biosimilars Market Average Price (2020-2031)
1.5 Assumptions and Limitations
2 Omalizumab Biosimilars Market Competition by Manufacturers
2.1 Global Omalizumab Biosimilars Sales Market Share by Manufacturers (2020-2025)
2.2 Global Omalizumab Biosimilars Revenue Market Share by Manufacturers (2020-2025)
2.3 Global Omalizumab Biosimilars Average Price by Manufacturers (2020-2025)
2.4 Global Key Players of Omalizumab Biosimilars, Industry Ranking, 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Omalizumab Biosimilars, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Omalizumab Biosimilars, Product Type & Application
2.7 Global Key Manufacturers of Omalizumab Biosimilars, Date of Enter into This Industry
2.8 Global Omalizumab Biosimilars Market Competitive Situation and Trends
2.8.1 Global Omalizumab Biosimilars Market Concentration Rate
2.8.2 The Global 5 and 10 Largest Omalizumab Biosimilars Players Market Share by Revenue
2.8.3 Global Omalizumab Biosimilars Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global Omalizumab Biosimilars Market Scenario by Region
3.1 Global Omalizumab Biosimilars Market Size by Region: 2020 Versus 2024 Versus 2031
3.2 Global Omalizumab Biosimilars Sales by Region: 2020-2031
3.2.1 Global Omalizumab Biosimilars Sales by Region: 2020-2025
3.2.2 Global Omalizumab Biosimilars Sales by Region: 2026-2031
3.3 Global Omalizumab Biosimilars Revenue by Region: 2020-2031
3.3.1 Global Omalizumab Biosimilars Revenue by Region: 2020-2025
3.3.2 Global Omalizumab Biosimilars Revenue by Region: 2026-2031
3.4 North America Omalizumab Biosimilars Market Facts & Figures by Country
3.4.1 North America Omalizumab Biosimilars Market Size by Country: 2020 VS 2024 VS 2031
3.4.2 North America Omalizumab Biosimilars Sales by Country (2020-2031)
3.4.3 North America Omalizumab Biosimilars Revenue by Country (2020-2031)
3.4.4 U.S.
3.4.5 Canada
3.5 Europe Omalizumab Biosimilars Market Facts & Figures by Country
3.5.1 Europe Omalizumab Biosimilars Market Size by Country: 2020 VS 2024 VS 2031
3.5.2 Europe Omalizumab Biosimilars Sales by Country (2020-2031)
3.5.3 Europe Omalizumab Biosimilars Revenue by Country (2020-2031)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Omalizumab Biosimilars Market Facts & Figures by Region
3.6.1 Asia Pacific Omalizumab Biosimilars Market Size by Region: 2020 VS 2024 VS 2031
3.6.2 Asia Pacific Omalizumab Biosimilars Sales by Region (2020-2031)
3.6.3 Asia Pacific Omalizumab Biosimilars Revenue by Region (2020-2031)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.6.13 Philippines
3.7 Latin America Omalizumab Biosimilars Market Facts & Figures by Country
3.7.1 Latin America Omalizumab Biosimilars Market Size by Country: 2020 VS 2024 VS 2031
3.7.2 Latin America Omalizumab Biosimilars Sales by Country (2020-2031)
3.7.3 Latin America Omalizumab Biosimilars Revenue by Country (2020-2031)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Omalizumab Biosimilars Market Facts & Figures by Country
3.8.1 Middle East and Africa Omalizumab Biosimilars Market Size by Country: 2020 VS 2024 VS 2031
3.8.2 Middle East and Africa Omalizumab Biosimilars Sales by Country (2020-2031)
3.8.3 Middle East and Africa Omalizumab Biosimilars Revenue by Country (2020-2031)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 U.A.E
4 Segment by Type
4.1 Global Omalizumab Biosimilars Sales by Type (2020-2031)
4.1.1 Global Omalizumab Biosimilars Sales by Type (2020-2025)
4.1.2 Global Omalizumab Biosimilars Sales by Type (2026-2031)
4.1.3 Global Omalizumab Biosimilars Sales Market Share by Type (2020-2031)
4.2 Global Omalizumab Biosimilars Revenue by Type (2020-2031)
4.2.1 Global Omalizumab Biosimilars Revenue by Type (2020-2025)
4.2.2 Global Omalizumab Biosimilars Revenue by Type (2026-2031)
4.2.3 Global Omalizumab Biosimilars Revenue Market Share by Type (2020-2031)
4.3 Global Omalizumab Biosimilars Price by Type (2020-2031)
5 Segment by Application
5.1 Global Omalizumab Biosimilars Sales by Application (2020-2031)
5.1.1 Global Omalizumab Biosimilars Sales by Application (2020-2025)
5.1.2 Global Omalizumab Biosimilars Sales by Application (2026-2031)
5.1.3 Global Omalizumab Biosimilars Sales Market Share by Application (2020-2031)
5.2 Global Omalizumab Biosimilars Revenue by Application (2020-2031)
5.2.1 Global Omalizumab Biosimilars Revenue by Application (2020-2025)
5.2.2 Global Omalizumab Biosimilars Revenue by Application (2026-2031)
5.2.3 Global Omalizumab Biosimilars Revenue Market Share by Application (2020-2031)
5.3 Global Omalizumab Biosimilars Price by Application (2020-2031)
6 Key Companies Profiled
6.1 Roche
6.1.1 Roche Company Information
6.1.2 Roche Description and Business Overview
6.1.3 Roche Omalizumab Biosimilars Sales, Revenue and Gross Margin (2020-2025)
6.1.4 Roche Omalizumab Biosimilars Product Portfolio
6.1.5 Roche Recent Developments/Updates
6.2 Novartis
6.2.1 Novartis Company Information
6.2.2 Novartis Description and Business Overview
6.2.3 Novartis Omalizumab Biosimilars Sales, Revenue and Gross Margin (2020-2025)
6.2.4 Novartis Omalizumab Biosimilars Product Portfolio
6.2.5 Novartis Recent Developments/Updates
6.3 Glenmark Pharmaceuticals
6.3.1 Glenmark Pharmaceuticals Company Information
6.3.2 Glenmark Pharmaceuticals Description and Business Overview
6.3.3 Glenmark Pharmaceuticals Omalizumab Biosimilars Sales, Revenue and Gross Margin (2020-2025)
6.3.4 Glenmark Pharmaceuticals Omalizumab Biosimilars Product Portfolio
6.3.5 Glenmark Pharmaceuticals Recent Developments/Updates
6.4 Selexis
6.4.1 Selexis Company Information
6.4.2 Selexis Description and Business Overview
6.4.3 Selexis Omalizumab Biosimilars Sales, Revenue and Gross Margin (2020-2025)
6.4.4 Selexis Omalizumab Biosimilars Product Portfolio
6.4.5 Selexis Recent Developments/Updates
6.5 Generium
6.5.1 Generium Company Information
6.5.2 Generium Description and Business Overview
6.5.3 Generium Omalizumab Biosimilars Sales, Revenue and Gross Margin (2020-2025)
6.5.4 Generium Omalizumab Biosimilars Product Portfolio
6.5.5 Generium Recent Developments/Updates
6.6 CuraTeQ
6.6.1 CuraTeQ Company Information
6.6.2 CuraTeQ Description and Business Overview
6.6.3 CuraTeQ Omalizumab Biosimilars Sales, Revenue and Gross Margin (2020-2025)
6.6.4 CuraTeQ Omalizumab Biosimilars Product Portfolio
6.6.5 CuraTeQ Recent Developments/Updates
6.7 Celltrion Healthcare
6.7.1 Celltrion Healthcare Company Information
6.7.2 Celltrion Healthcare Description and Business Overview
6.7.3 Celltrion Healthcare Omalizumab Biosimilars Sales, Revenue and Gross Margin (2020-2025)
6.7.4 Celltrion Healthcare Omalizumab Biosimilars Product Portfolio
6.7.5 Celltrion Healthcare Recent Developments/Updates
6.8 Alvotech
6.8.1 Alvotech Company Information
6.8.2 Alvotech Description and Business Overview
6.8.3 Alvotech Omalizumab Biosimilars Sales, Revenue and Gross Margin (2020-2025)
6.8.4 Alvotech Omalizumab Biosimilars Product Portfolio
6.8.5 Alvotech Recent Developments/Updates
6.9 BiosanaPharma
6.9.1 BiosanaPharma Company Information
6.9.2 BiosanaPharma Description and Business Overview
6.9.3 BiosanaPharma Omalizumab Biosimilars Sales, Revenue and Gross Margin (2020-2025)
6.9.4 BiosanaPharma Omalizumab Biosimilars Product Portfolio
6.9.5 BiosanaPharma Recent Developments/Updates
6.10 Mabpharm
6.10.1 Mabpharm Company Information
6.10.2 Mabpharm Description and Business Overview
6.10.3 Mabpharm Omalizumab Biosimilars Sales, Revenue and Gross Margin (2020-2025)
6.10.4 Mabpharm Omalizumab Biosimilars Product Portfolio
6.10.5 Mabpharm Recent Developments/Updates
6.11 CSPC Pharmaceutical Group
6.11.1 CSPC Pharmaceutical Group Company Information
6.11.2 CSPC Pharmaceutical Group Description and Business Overview
6.11.3 CSPC Pharmaceutical Group Omalizumab Biosimilars Sales, Revenue and Gross Margin (2020-2025)
6.11.4 CSPC Pharmaceutical Group Omalizumab Biosimilars Product Portfolio
6.11.5 CSPC Pharmaceutical Group Recent Developments/Updates
6.12 Biomabs
6.12.1 Biomabs Company Information
6.12.2 Biomabs Description and Business Overview
6.12.3 Biomabs Omalizumab Biosimilars Sales, Revenue and Gross Margin (2020-2025)
6.12.4 Biomabs Omalizumab Biosimilars Product Portfolio
6.12.5 Biomabs Recent Developments/Updates
6.13 HisunPharm
6.13.1 HisunPharm Company Information
6.13.2 HisunPharm Description and Business Overview
6.13.3 HisunPharm Omalizumab Biosimilars Sales, Revenue and Gross Margin (2020-2025)
6.13.4 HisunPharm Omalizumab Biosimilars Product Portfolio
6.13.5 HisunPharm Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Omalizumab Biosimilars Industry Chain Analysis
7.2 Omalizumab Biosimilars Raw Material Supply Analysis
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Omalizumab Biosimilars Production Mode & Process Analysis
7.4 Omalizumab Biosimilars Sales and Marketing
7.4.1 Omalizumab Biosimilars Sales Channels
7.4.2 Omalizumab Biosimilars Distributors
7.5 Omalizumab Biosimilars Customer Analysis
8 Omalizumab Biosimilars Market Dynamics
8.1 Omalizumab Biosimilars Industry Trends
8.2 Omalizumab Biosimilars Market Drivers
8.3 Omalizumab Biosimilars Market Challenges
8.4 Omalizumab Biosimilars Market Restraints
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
FEATURED COMPANIES
Roche
Novartis
Glenmark Pharmaceuticals
Selexis
Generium
Celltrion Healthcare
Alvotech
CSPC Pharmaceutical Group
CuraTeQ
BiosanaPharma
Mabpharm
Biomabs
HisunPharm
List of Tables
 Table 1. Global Omalizumab Biosimilars Market Value Comparison by Type (2024 VS 2031) & (US$ Million)
 Table 2. Global Omalizumab Biosimilars Market Value by Application (2024 VS 2031) & (US$ Million)
 Table 3. Global Omalizumab Biosimilars Market Competitive Situation by Manufacturers in 2024
 Table 4. Global Omalizumab Biosimilars Sales (K Units) of Key Manufacturers (2020-2025)
 Table 5. Global Omalizumab Biosimilars Sales Market Share by Manufacturers (2020-2025)
 Table 6. Global Omalizumab Biosimilars Revenue (US$ Million) by Manufacturers (2020-2025)
 Table 7. Global Omalizumab Biosimilars Revenue Share by Manufacturers (2020-2025)
 Table 8. Global Market Omalizumab Biosimilars Average Price (USD/Unit) of Key Manufacturers (2020-2025)
 Table 9. Global Key Players of Omalizumab Biosimilars, Industry Ranking, 2022 VS 2023 VS 2024
 Table 10. Global Key Manufacturers of Omalizumab Biosimilars, Manufacturing Sites & Headquarters
 Table 11. Global Key Manufacturers of Omalizumab Biosimilars, Product Type & Application
 Table 12. Global Key Manufacturers of Omalizumab Biosimilars, Date of Enter into This Industry
 Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
 Table 14. Global Omalizumab Biosimilars by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Omalizumab Biosimilars as of 2024)
 Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
 Table 16. Global Omalizumab Biosimilars Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
 Table 17. Global Omalizumab Biosimilars Sales by Region (2020-2025) & (K Units)
 Table 18. Global Omalizumab Biosimilars Sales Market Share by Region (2020-2025)
 Table 19. Global Omalizumab Biosimilars Sales by Region (2026-2031) & (K Units)
 Table 20. Global Omalizumab Biosimilars Sales Market Share by Region (2026-2031)
 Table 21. Global Omalizumab Biosimilars Revenue by Region (2020-2025) & (US$ Million)
 Table 22. Global Omalizumab Biosimilars Revenue Market Share by Region (2020-2025)
 Table 23. Global Omalizumab Biosimilars Revenue by Region (2026-2031) & (US$ Million)
 Table 24. Global Omalizumab Biosimilars Revenue Market Share by Region (2026-2031)
 Table 25. North America Omalizumab Biosimilars Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 26. North America Omalizumab Biosimilars Sales by Country (2020-2025) & (K Units)
 Table 27. North America Omalizumab Biosimilars Sales by Country (2026-2031) & (K Units)
 Table 28. North America Omalizumab Biosimilars Revenue by Country (2020-2025) & (US$ Million)
 Table 29. North America Omalizumab Biosimilars Revenue by Country (2026-2031) & (US$ Million)
 Table 30. Europe Omalizumab Biosimilars Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 31. Europe Omalizumab Biosimilars Sales by Country (2020-2025) & (K Units)
 Table 32. Europe Omalizumab Biosimilars Sales by Country (2026-2031) & (K Units)
 Table 33. Europe Omalizumab Biosimilars Revenue by Country (2020-2025) & (US$ Million)
 Table 34. Europe Omalizumab Biosimilars Revenue by Country (2026-2031) & (US$ Million)
 Table 35. Asia Pacific Omalizumab Biosimilars Revenue by Region: 2020 VS 2024 VS 2031 (US$ Million)
 Table 36. Asia Pacific Omalizumab Biosimilars Sales by Region (2020-2025) & (K Units)
 Table 37. Asia Pacific Omalizumab Biosimilars Sales by Region (2026-2031) & (K Units)
 Table 38. Asia Pacific Omalizumab Biosimilars Revenue by Region (2020-2025) & (US$ Million)
 Table 39. Asia Pacific Omalizumab Biosimilars Revenue by Region (2026-2031) & (US$ Million)
 Table 40. Latin America Omalizumab Biosimilars Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 41. Latin America Omalizumab Biosimilars Sales by Country (2020-2025) & (K Units)
 Table 42. Latin America Omalizumab Biosimilars Sales by Country (2026-2031) & (K Units)
 Table 43. Latin America Omalizumab Biosimilars Revenue by Country (2020-2025) & (US$ Million)
 Table 44. Latin America Omalizumab Biosimilars Revenue by Country (2026-2031) & (US$ Million)
 Table 45. Middle East and Africa Omalizumab Biosimilars Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 46. Middle East and Africa Omalizumab Biosimilars Sales by Country (2020-2025) & (K Units)
 Table 47. Middle East and Africa Omalizumab Biosimilars Sales by Country (2026-2031) & (K Units)
 Table 48. Middle East and Africa Omalizumab Biosimilars Revenue by Country (2020-2025) & (US$ Million)
 Table 49. Middle East and Africa Omalizumab Biosimilars Revenue by Country (2026-2031) & (US$ Million)
 Table 50. Global Omalizumab Biosimilars Sales (K Units) by Type (2020-2025)
 Table 51. Global Omalizumab Biosimilars Sales (K Units) by Type (2026-2031)
 Table 52. Global Omalizumab Biosimilars Sales Market Share by Type (2020-2025)
 Table 53. Global Omalizumab Biosimilars Sales Market Share by Type (2026-2031)
 Table 54. Global Omalizumab Biosimilars Revenue (US$ Million) by Type (2020-2025)
 Table 55. Global Omalizumab Biosimilars Revenue (US$ Million) by Type (2026-2031)
 Table 56. Global Omalizumab Biosimilars Revenue Market Share by Type (2020-2025)
 Table 57. Global Omalizumab Biosimilars Revenue Market Share by Type (2026-2031)
 Table 58. Global Omalizumab Biosimilars Price (USD/Unit) by Type (2020-2025)
 Table 59. Global Omalizumab Biosimilars Price (USD/Unit) by Type (2026-2031)
 Table 60. Global Omalizumab Biosimilars Sales (K Units) by Application (2020-2025)
 Table 61. Global Omalizumab Biosimilars Sales (K Units) by Application (2026-2031)
 Table 62. Global Omalizumab Biosimilars Sales Market Share by Application (2020-2025)
 Table 63. Global Omalizumab Biosimilars Sales Market Share by Application (2026-2031)
 Table 64. Global Omalizumab Biosimilars Revenue (US$ Million) by Application (2020-2025)
 Table 65. Global Omalizumab Biosimilars Revenue (US$ Million) by Application (2026-2031)
 Table 66. Global Omalizumab Biosimilars Revenue Market Share by Application (2020-2025)
 Table 67. Global Omalizumab Biosimilars Revenue Market Share by Application (2026-2031)
 Table 68. Global Omalizumab Biosimilars Price (USD/Unit) by Application (2020-2025)
 Table 69. Global Omalizumab Biosimilars Price (USD/Unit) by Application (2026-2031)
 Table 70. Roche Company Information
 Table 71. Roche Description and Business Overview
 Table 72. Roche Omalizumab Biosimilars Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
 Table 73. Roche Omalizumab Biosimilars Product
 Table 74. Roche Recent Developments/Updates
 Table 75. Novartis Company Information
 Table 76. Novartis Description and Business Overview
 Table 77. Novartis Omalizumab Biosimilars Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
 Table 78. Novartis Omalizumab Biosimilars Product
 Table 79. Novartis Recent Developments/Updates
 Table 80. Glenmark Pharmaceuticals Company Information
 Table 81. Glenmark Pharmaceuticals Description and Business Overview
 Table 82. Glenmark Pharmaceuticals Omalizumab Biosimilars Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
 Table 83. Glenmark Pharmaceuticals Omalizumab Biosimilars Product
 Table 84. Glenmark Pharmaceuticals Recent Developments/Updates
 Table 85. Selexis Company Information
 Table 86. Selexis Description and Business Overview
 Table 87. Selexis Omalizumab Biosimilars Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
 Table 88. Selexis Omalizumab Biosimilars Product
 Table 89. Selexis Recent Developments/Updates
 Table 90. Generium Company Information
 Table 91. Generium Description and Business Overview
 Table 92. Generium Omalizumab Biosimilars Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
 Table 93. Generium Omalizumab Biosimilars Product
 Table 94. Generium Recent Developments/Updates
 Table 95. CuraTeQ Company Information
 Table 96. CuraTeQ Description and Business Overview
 Table 97. CuraTeQ Omalizumab Biosimilars Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
 Table 98. CuraTeQ Omalizumab Biosimilars Product
 Table 99. CuraTeQ Recent Developments/Updates
 Table 100. Celltrion Healthcare Company Information
 Table 101. Celltrion Healthcare Description and Business Overview
 Table 102. Celltrion Healthcare Omalizumab Biosimilars Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
 Table 103. Celltrion Healthcare Omalizumab Biosimilars Product
 Table 104. Celltrion Healthcare Recent Developments/Updates
 Table 105. Alvotech Company Information
 Table 106. Alvotech Description and Business Overview
 Table 107. Alvotech Omalizumab Biosimilars Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
 Table 108. Alvotech Omalizumab Biosimilars Product
 Table 109. Alvotech Recent Developments/Updates
 Table 110. BiosanaPharma Company Information
 Table 111. BiosanaPharma Description and Business Overview
 Table 112. BiosanaPharma Omalizumab Biosimilars Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
 Table 113. BiosanaPharma Omalizumab Biosimilars Product
 Table 114. BiosanaPharma Recent Developments/Updates
 Table 115. Mabpharm Company Information
 Table 116. Mabpharm Description and Business Overview
 Table 117. Mabpharm Omalizumab Biosimilars Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
 Table 118. Mabpharm Omalizumab Biosimilars Product
 Table 119. Mabpharm Recent Developments/Updates
 Table 120. CSPC Pharmaceutical Group Company Information
 Table 121. CSPC Pharmaceutical Group Description and Business Overview
 Table 122. CSPC Pharmaceutical Group Omalizumab Biosimilars Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
 Table 123. CSPC Pharmaceutical Group Omalizumab Biosimilars Product
 Table 124. CSPC Pharmaceutical Group Recent Developments/Updates
 Table 125. Biomabs Company Information
 Table 126. Biomabs Description and Business Overview
 Table 127. Biomabs Omalizumab Biosimilars Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
 Table 128. Biomabs Omalizumab Biosimilars Product
 Table 129. Biomabs Recent Developments/Updates
 Table 130. HisunPharm Company Information
 Table 131. HisunPharm Description and Business Overview
 Table 132. HisunPharm Omalizumab Biosimilars Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
 Table 133. HisunPharm Omalizumab Biosimilars Product
 Table 134. HisunPharm Recent Developments/Updates
 Table 135. Key Raw Materials Lists
 Table 136. Raw Materials Key Suppliers Lists
 Table 137. Omalizumab Biosimilars Distributors List
 Table 138. Omalizumab Biosimilars Customers List
 Table 139. Omalizumab Biosimilars Market Trends
 Table 140. Omalizumab Biosimilars Market Drivers
 Table 141. Omalizumab Biosimilars Market Challenges
 Table 142. Omalizumab Biosimilars Market Restraints
 Table 143. Research Programs/Design for This Report
 Table 144. Key Data Information from Secondary Sources
 Table 145. Key Data Information from Primary Sources
 Table 146. Authors List of This Report


List of Figures
 Figure 1. Product Picture of Omalizumab Biosimilars
 Figure 2. Global Omalizumab Biosimilars Market Value Comparison by Type (2020-2031) & (US$ Million)
 Figure 3. Global Omalizumab Biosimilars Market Share by Type: 2024 & 2031
 Figure 4. 150 mg/mL Product Picture
 Figure 5. 75 mg/0.5 mL Product Picture
 Figure 6. Global Omalizumab Biosimilars Market Value by Application (2020-2031) & (US$ Million)
 Figure 7. Global Omalizumab Biosimilars Market Share by Application: 2024 & 2031
 Figure 8. Persistent Asthma
 Figure 9. Nasal Polyps
 Figure 10. Chronic Idiopathic Urticaria
 Figure 11. Global Omalizumab Biosimilars Revenue, (US$ Million), 2020 VS 2024 VS 2031
 Figure 12. Global Omalizumab Biosimilars Market Size (2020-2031) & (US$ Million)
 Figure 13. Global Omalizumab Biosimilars Sales (2020-2031) & (K Units)
 Figure 14. Global Omalizumab Biosimilars Average Price (USD/Unit) & (2020-2031)
 Figure 15. Omalizumab Biosimilars Report Years Considered
 Figure 16. Omalizumab Biosimilars Sales Share by Manufacturers in 2024
 Figure 17. Global Omalizumab Biosimilars Revenue Share by Manufacturers in 2024
 Figure 18. Global 5 and 10 Largest Omalizumab Biosimilars Players: Market Share by Revenue in Omalizumab Biosimilars in 2024
 Figure 19. Omalizumab Biosimilars Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
 Figure 20. Global Omalizumab Biosimilars Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
 Figure 21. North America Omalizumab Biosimilars Sales Market Share by Country (2020-2031)
 Figure 22. North America Omalizumab Biosimilars Revenue Market Share by Country (2020-2031)
 Figure 23. U.S. Omalizumab Biosimilars Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 24. Canada Omalizumab Biosimilars Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 25. Europe Omalizumab Biosimilars Sales Market Share by Country (2020-2031)
 Figure 26. Europe Omalizumab Biosimilars Revenue Market Share by Country (2020-2031)
 Figure 27. Germany Omalizumab Biosimilars Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 28. France Omalizumab Biosimilars Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 29. U.K. Omalizumab Biosimilars Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 30. Italy Omalizumab Biosimilars Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 31. Russia Omalizumab Biosimilars Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 32. Asia Pacific Omalizumab Biosimilars Sales Market Share by Region (2020-2031)
 Figure 33. Asia Pacific Omalizumab Biosimilars Revenue Market Share by Region (2020-2031)
 Figure 34. China Omalizumab Biosimilars Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 35. Japan Omalizumab Biosimilars Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 36. South Korea Omalizumab Biosimilars Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 37. India Omalizumab Biosimilars Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 38. Australia Omalizumab Biosimilars Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 39. Taiwan Omalizumab Biosimilars Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 40. Indonesia Omalizumab Biosimilars Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 41. Thailand Omalizumab Biosimilars Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 42. Malaysia Omalizumab Biosimilars Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 43. Philippines Omalizumab Biosimilars Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 44. Latin America Omalizumab Biosimilars Sales Market Share by Country (2020-2031)
 Figure 45. Latin America Omalizumab Biosimilars Revenue Market Share by Country (2020-2031)
 Figure 46. Mexico Omalizumab Biosimilars Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 47. Brazil Omalizumab Biosimilars Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 48. Argentina Omalizumab Biosimilars Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 49. Middle East and Africa Omalizumab Biosimilars Sales Market Share by Country (2020-2031)
 Figure 50. Middle East and Africa Omalizumab Biosimilars Revenue Market Share by Country (2020-2031)
 Figure 51. Turkey Omalizumab Biosimilars Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 52. Saudi Arabia Omalizumab Biosimilars Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 53. U.A.E Omalizumab Biosimilars Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 54. Global Sales Market Share of Omalizumab Biosimilars by Type (2020-2031)
 Figure 55. Global Revenue Market Share of Omalizumab Biosimilars by Type (2020-2031)
 Figure 56. Global Omalizumab Biosimilars Price (USD/Unit) by Type (2020-2031)
 Figure 57. Global Sales Market Share of Omalizumab Biosimilars by Application (2020-2031)
 Figure 58. Global Revenue Market Share of Omalizumab Biosimilars by Application (2020-2031)
 Figure 59. Global Omalizumab Biosimilars Price (USD/Unit) by Application (2020-2031)
 Figure 60. Omalizumab Biosimilars Value Chain
 Figure 61. Channels of Distribution (Direct Vs Distribution)
 Figure 62. Bottom-up and Top-down Approaches for This Report
 Figure 63. Data Triangulation
 Figure 64. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$2900

This license allows only one user to access the PDF.
Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)
INQUIRE FOR DISCOUNT

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Strategic Venue Partners

SIMILAR REPORTS

Infliximab and Biosimilar Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Tocilizumab Biosimilars Market Research Report 2024
Trastuzumab Biosimilar Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Ranibizumab Drugs and Biosimilars Market Research Report 2024
Global Adalimumab Infliximab And Etanercept Biosimilars Market Research Report 2024
Oncology Biosimilars Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Rituximab Biosimilars Market Research Report 2025
Allergic Rhinitis Medication Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Hay Fever and Allergic Rhinitis Therapeutics Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Recombinant Glycosylated Proteins Biosimilar Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global IgE Allergy Blood Test Kits Market Research Report 2025
Global Allergic Asthma Therapeutics Market Research Report 2025
Global Omalizumab Monoclonal Antibody Biosimilars Market Research Report 2024
Global Omalizumab for Injection Market Research Report 2024
Global Ustekinumab Biosimilars Market Research Report 2024
Global Monoclonal antibodies mAbs Biosimilars Market Research Report 2024
Global Raibizumab Biosimilars Market Research Report 2025
Anti Allergy Medicine Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
IgE Allergy Blood Tests Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Inhaled Allergens Allergy Diagnostics Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Call
Buy Now
REQUEST FREE SAMPLE REPORT
Support Contacts
U.S. (TOLL FREE)
+1 (425) 388-2538
THE COMPANY
OUR PRODUCTS
CUSTOMER SUPPORT
POLICES
THE COMPANY
CUSTOMER SUPPORT
OUR PRODUCTS
POLICES
Copyright © 2018 Valuates.com. All Rights Reserved.
Sitemap - Privacy Policy - Terms & Conditions